Relation of coronary collateral circulation with epicardial fat volume in patients with stable coronary artery disease

Asim Enhos, Irfan Sahin, Mehmet Mustafa Can, Ibrahim Biter, Mustafa Hakan Dinckal, Victor Serebruany
Bagcilar Research and Education Hospital, Cardiology Department, Bagcilar 34800, Istanbul, Turkey

Abstract

Objective To investigate the relationship between epicardial fat volume (EFV) and coronary collateral circulation (CCC) in patients with stable coronary artery disease (CAD). Methods The study population consisted of 152 consecutive patients with CAD who underwent coronary angiography and were found to have at least 95% significant lesion in at least one major coronary artery. EFV was assessed utilizing 64-multislice computed tomography. The patients were classified into impaired CCC group (Group 1, Rentrop grades 0−1, n = 58), or adequate CCC (Group 2, Rentrop grades 2−3, n = 94). Results The EFV values were significantly higher in patients with adequate CCC than in those with impaired CCC. In multivariate logistic regression analysis, EFV (OR = 1.059; 95% CI: 1.035−1.085; P = 0.001); and presence of angina were independent predictors of adequate CCC. In receiver-operating characteristic curve analysis, the EFV value > 106.5 mL yielded an area under the curve value of 0.84, with the test sensitivity of 49.3%, and with 98.3% specificity. Conclusions High EFV, and the presence of angina independently predict adequate CCC in patients with stable coronary artery disease. This association offers new diagnostic opportunities to assess collateral flow by conventional ultrasound techniques.

Keywords: Epicardial adipose tissue; Coronary artery disease; Angina; Collateral circulation

1 Introduction

Coronary collateral circulation (CCC) is an adaptive compensatory response to myocardial ischemia.[1] In addition, CCC is an alternative source of blood supply to the myocardium which can be jeopardized by the failure of the original stenotic, or occluded vessel, to provide adequate blood flow to the targeted ischemic region.[2] There are multiple collateral coronary arteries connecting to the normal coronary arteries in individuals without documented coronary artery disease (CAD); however, most of these additional vessels are not angiographically visible.[3,4] In contrast, patients with coronary stenosis, or occlusion, develop various visible CCC. A well-developed CCC has a favourable impact on the prognosis of patients with CAD by minimizing infarct size, reducing evolution of left ventricular aneurysm formation, improving ventricular function, and may lead to improved survival.[5−7]

Epicardial fat volume (EFV) is a biomarker of visceral adipose tissue that has been shown to be correlated with adverse cardiovascular events, both short, and long-term.[8−10] Endothelial dysfunction, and structural changes of the microcirculation are well established features of patients with increased EFV.[11−13] On the other hand, the relationship between EFV and CCC is still unclear. Therefore, we sought to investigate the relationship between EFV level and CCC in patients with CAD.

2 Methods

2.1 Study population

The study was approved by the institutional ethics committee. The study population consisted of 400 consecutive patients with stable CAD who underwent coronary angiography. The patients with a history of coronary angiogram showing a lesion of < 80% stenosis, history of percutaneous coronary intervention, or coronary artery bypass grafting were excluded from the analyses. Finally, 152 patients with stable CAD were included in our study. The clinical risk factors for the patients, such as age, gender, hypertension, diabetes mellitus (DM), history of hyperlipidemia, smoking status, and family history, were recorded.
Hypertension was defined as systolic blood pressure >140 mmHg and/or diastolic pressure >90 mmHg at least two times, or if the individual was taking antihypertensive medications. The diagnosis of DM was based on the previous history of diabetes treated with, or without, drug therapies. Current smokers were defined as those who had smoked for some period during the past year. Furthermore, on admission, each patient was evaluated for blood pressure, heart rate, previously used drugs, presence of angina, high sensitivity C-reactive protein (hs-CRP), serum creatinine, glucose, lipid profile and hematological indices. Also each patient underwent transthoracic echocardiography using the biplane Simpson method measuring left ventricular ejection fraction (LVEF). Hematological indices were measured as part of the automated complete blood count (CBC) using a Coulter LH 780 Hematology Analyzer (Beckman Coulter Ireland Inc, Mervue, Galway, Ireland).

2.2 Coronary angiography

Quantitative coronary angiography was performed using standard Judkins method via transfemoral route. The inclusion criteria were the presence of 80%, or greater, degree of diameter stenosis in at least one coronary artery. Therefore, since development of CCC is known to be inadequate in patients not complying with this criteria, they were excluded from the index study. The CCC was graded according to the Reentrop classification. Accordingly, Grade 0 was classified as no filling; Grade 1 classified as filling of side branches via collateral channels without visualization of the epicardial segment; Grade 2 classified as a partial filling of epicardial major coronary artery via collateral channels; and Grade 3 classified as complete filling of epicardial major coronary artery. In patients with more than one coronary lesion, and when there was more than one CCC, the CCC with the highest Reentrop was used. The patients were classified into impaired CCC (Group 1, Reentrop grades 0–1) or adequate CCC (Group 2, Reentrop grades 2–3). Multivessel disease was defined as the presence of a lesion in two, or more major epicardial arteries.

2.3 Statistical analysis

Continuous variables are expressed as mean ±SD, whereas categorical variables are expressed as percentage. Comparisons between two CCC groups were made using the Student t test or Mann-Whitney U test or Chi square tests, as appropriate. Comparison between Rentrop grades were made using the analysis of variance, and Turkey honestly significant difference test was chosen as a post hoc test. Multiple logistic regression analysis was performed to identify the independent predictors of CCC using variables showing marginal association with it on univariate testing (P < 0.01). Receiver-operating characteristics (ROC) analyses were used to detect the cutoff value of EFV in the prediction of CCC. Correlation analysis between variables were performed using Pearson or Spearman correlation. P < 0.05 was considered significant. All statistical analyses were carried out using SPSS 16.0 for Windows (SPSS Inc, Chicago, Illinois).

Table 1. Baseline characteristics according to coronary collateral circulation.

| Variable                  | Impaired CCC (n = 58) | Adequate CCC (n = 94) | P   |
|---------------------------|-----------------------|-----------------------|-----|
| Age (yrs)                 | 65.65 ± 10.65         | 65.14 ± 10.34         | 0.765|
| Sex, male                 | 48 (64.0)             | 59 (76.6)             | 0.088|
| Diabetess                  | 43 (53.8)             | 37 (46.2)             | 0.252|
| Hypertension              | 55 (73.3)             | 54 (70.1)             | 0.661|
| Smoking                   | 36 (48.0)             | 52 (67.5)             | 0.008|
| Family history of CAD     | 31 (41.3)             | 30 (39.0)             | 0.368|
| BMI, kg/m²                 | 27 ± 3.0              | 22 ± 6.9              | 0.08 |
| Presence of angina        | 52 (69.3)             | 38 (49.4)             | 0.006|
| Heart rate                | 79.2 ± 8.54           | 74.3 ± 6.87           | 0.246|
| Systolic blood pressure, mm Hg | 138 ± 12             | 131 ± 11              | 0.368|
| Diastolic blood pressure, mm Hg | 86 ± 7               | 87 ± 8                | 0.589|
| LVEF                      | 49.6 ± 7.5            | 48 ± 8                | 0.4  |
| White blood cell count, × 10⁹ | 9.1 ± 2.95           | 8.6 ± 3.08            | 0.285|
| Platelet count, × 10⁹     | 188.2 ± 12.6          | 184.6 ± 11.5          | 0.489|
| Red cell distribution width, % | 15.4 ± 1.5           | 12.9 ± 1.8            | 0.085|
| Mean platelet volume, mL × 10⁻¹ | 9.82 ± 0.97       | 8.33 ± 1.07           | 0.004|
| Estimated GFR, mL/min per 1.73 m² | 82.04 ± 14.57        | 76.33 ± 12.52         | 0.160|
| Oxygen Saturation         | 96.4 ± 0.8            | 96.2 ± 0.9            | 0.624|
| Previous medications, %   |                       |                       |     |
| Aspirin                   | 85.3                  | 87                    | 0.339|
| Beta-blocker              | 83.3                  | 85                    | 0.339|
| Statin                    | 63.6                  | 66.5                  | 0.4  |
| ACE-inhibitors/ARB        | 46.6                  | 44.5                  | 0.6  |
| CCB                       | 35                    | 36                    | 0.339|
| OAD                       | 83.3                  | 85                    | 0.339|
| Insulin                   | 24                    | 22                    | 0.256|
| Diuretic                  | 6.6                   | 6.5                   | 0.448|
| LDL-cholesterol, mg/dL    | 124 ± 37.2            | 120 ± 31              | 0.6  |
| HDL-Cholesterol, mg/dL    | 34 ± 8                | 36 ± 9                | 0.8  |
| Triglyceride, mg/dL       | 207 ± 68              | 168 ± 66              | 0.09 |
| hs-CRP, mg/dL             | 6.0 ± 6.1             | 4.5 ± 3.3             | 0.03 |
| Multivessel disease, %    | 58                    | 56                    | 0.8  |
| EFV, mL                   | 88 ± 33               | 114 ± 47              | 0.001|

Data are presented as mean ± SD, or n (%). ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker; BMI: body mass index; CAD: coronary artery disease; CCB: calcium channel blocker; CCC: coronary collateral circulation; hs-CRP: high sensitivity C-reactive protein; EFV: epicardial fat volume; GFR: glomerular filtration rate; HDL: high-density lipoprotein; hs-OAD: oral antidiabetic drug; LDL: low-density lipoprotein; LVEF: left ventricular ejection fraction.
3 Results

A total of 152 patients with stable CAD (Age: 65 ± 10 years, male ratio: 70%) were included in the study. Table 1 shows the comparison of Groups 1 and 2 relative to baseline characteristics. Compared to the patients with adequate CCC, patients with impaired CCC exhibited higher red cell distribution width (RDW), mean platelet volume (MPV), triglyceride (TG), hs-CRP values and frequency of BMI and preinfarction rates. Compared to the patients with impaired CCC, patients with adequate CCC manifested significantly higher EFV levels. Furthermore, Rentrop grade 2 and 3 patients had significantly higher EFV levels when compared to the Rentrop grade 0 and 1 patients. Multivariate logistic regression test was employed for determining the independent predictors of impaired CCC (Figure 1, Table 2). The variables that were found to have significance in the univariate analysis (preinfarction angina, RDW, MPV, TG, body mass index (BMI), hs-CRP) were included in the multivariate model. Among those, EFV (OR: 1.059; 95% CI (1.035–1.085); \(P\) = 0.00), presence of angina were found to be the independent predictors of adequate CCC. In receiver-operating characteristic curve analysis, the EFV value > 106.5 mL yielded an area under the curve value of 0.84, with 49.3% sensitivity and 98.3% specificity (Figure 2).

4 Discussion

Our study demonstrated that the presence of angina and high EFV levels may serve to be independent predictors of adequate CCC. The clinical significance of our findings is unclear, but may help in developing prediction models in the near future.

Coronary collateral vessels are structures that are normally present in the human heart, though being invisible by angiography.[3,4] These are interconnecting branches between the main arteries which serve as an alternative conduits for blood flow in obstructive coronary heart disease.[15] The CCC development occurs as a result of new vessel formation and growth of pre-existing arterioles (angiogenesis).[16] There are many factors influencing the development of the CCC, such as percent diameter of coronary artery stenosis, duration of angina, DM, hypertension smoking status, hypoxia, endothelial dysfunction, exercise, oxidative stress genetic factors, and drugs used.[1] A well-developed CCC has a favourable impact on the prognosis of patients with coronary artery disease by minimizing infarct size, reducing evolution of left ventricular aneurysm formation, improving ventricular function, and leading to improved survival.

Epicardial adipose tissue is a type of visceral adipose
tissue functioning as a metabolically active endocrine organ. The relationship between EFV presence and components of cardiovascular diseases have been described in several studies. Moreover, it has been shown that epicardial adipose tissue is in direct contact with the myocardium, and it is very metabolically active and can secrete a large number of cytokines and vasoactive peptides, including free fatty acids, interleukin-6, tumor necrosis factor (TNF)-α, angiotensin II, and plasminogen activator inhibitor-1. All of these molecules can independently play a role in terms of CCC development. Although the causes of CCC are completely unknown, one of the responsible mechanisms is thought to be the activation of immune sytems with predominant involvement of cytokines and chemokines. Cytokines, which are one of the important sources of inflammatory mediators, have emerged as key cellular determinants of progression of the CCC. Previous articles alerted the scientific community that hyper activation of cytokines and adhesion molecules which were in concordance with the severity of disease may give prognostic data about the severity of the CCC. Recent studies have shown that cytokines, which mediate the immune response to inflammatory disorders, were also secreted from epicardial adipocyte tissues. On the basis of these facts, EFV may be associated with the pathophysiologcal processes causing CCC. There are also several other pathogenic mechanisms thought to be the causative role for the association between increased EFV and the severity of the disease. Endothelial dysfunction plays a key role in terms of CCC development. Epicardial fat tissue seems to affect the endothelial function and increase sympathetic activity by its paracrine effect. Aydin et al. showed that EFV correlated with endothelial dysfunction assessed by flow-mediated dilatation in patients with metabolic syndrome. Based on these data, associated endothelial dysfunction can be considered as one of the mechanisms for predicting severity of CAD by assessing EFV levels.

There are a few limitations of the study worth mentioning. The present study findings do not prove a direct link between increased epicardial fat volume and the development of CCC. Although increased EFV could be a marker of CAD severity, and also be a predictive factor for adequate CCC, the possible causative effect of epicardial fat accumulation has not been clarified. Qualitative analysis of epicardial fat using biochemical techniques will be required to confirm the effect of accumulated epicardial fat on the progression of coronary atherosclerosis. The relatively small sample size is one of the major limitations of our study and certainly should be confirmed in a larger, better designed, randomized trial. Moreover, the cross-sectional design of our study makes it difficult to comment on the causal relationship of EFV and impaired CCC, and the observational design preclude us to adequately assess these important links. We conducted the index study in the experimental setting, and applied the observational design, therefore, not drawing any definite pathophysiologic mechanisms for the association between increased EFV and the severity of CCC. It is possible that similar mechanisms may be attributable for increase in EFV level in patients with CCC. Finally, one of the most important limitations was the failure to measure some parameters, such as FGF (fibroblast growth factor), vascular endothelial growth factor, NO, TNF-α that could be helpful in evaluating the relationship between EFV and impaired CCC in detail.

In conclusion, higher EFV level was associated with adequate CCC in patients with stable CAD. Further studies to investigate the cause and effect relationship between EFV and CCC are required.

References

1. Celik T, Celik M, Iyisoy A. Coronary collateral circulation. Turk Kardiyol Dern Ars 2010; 38: 505–514.
2. Seiler C. The human coronary collateral circulation. Heart 2003; 89: 1352–1357.
3. Levin DC. Pathways and functional significance of the coronary collateral circulation. Circulation 1974; 50: 831–837.
4. Elayda MA, Mathur VS, Hall RJ, et al. Collateral circulation in coronary artery disease. Am J Cardiol 1985; 55: 58–60.
5. Kodama K, Kusuoka H, Sakai A, et al. Collateral channels that develop after an acute myocardial infarction prevent subsequent left ventricular dilation. J Am Coll Cardiol 1996; 27: 1133–1139.
6. Rentrop KP, Thornton JC, Feit F, et al. Determinants and protective potential of coronary arterial collaterals as assessed by an angioplasty model. J Am Coll Cardiol 1988; 61: 677–684.
7. Werner GS, Surber R, Kuehle F, et al. Collaterals and the recovery of left ventricular function after recanalization of a chronic total coronary occlusion. Am Heart J 2005; 149: 129–137.
8. Gastaldelli A, Basta G. Ectopic fat and cardiovascular disease: what is the link? Nutr Metab Cardiovasc Dis 2010; 20: 481–490.
9. Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med 2005; 2: 536–543.
10. Nakazato R, Dey D, Cheng VY, et al. Epicardial fat volume and concurrent presence of both myocardial ischemia and obstructive coronary artery disease. Atherosclerosis 2012; 221: 422–426.
11. Ueno K, Anzai T, Jinzaki M, et al. Increased epicardial fat volume quantified by 64-multidetector computed tomography is associated with coronary atherosclerosis and totally occlu-
sive lesions. Circ J 2009; 73: 1927–1933.
12 Sade LE, Ergüloğlu S, Bozbah H, et al. Relation between epicardial fat thickness and coronary flow reserve in women with chest pain and angiographically normal coronary arteries. Atherosclerosis 2009; 204: 580–585.
13 Bachar GN, Dicker D, Kornowski R, et al. Epicardial adipose tissue as a predictor of coronary artery disease in asymptomatic subjects. Am J Cardiol 2012; 110: 534–538.
14 Rentrop KP, Thornton JC, Feit F, et al. Determinants and protective potential of coronary arterial collaterals as assessed by an angioplasty model. Am J Cardiol 1988; 61: 677–684.
15 Seiler C. The human coronary collateral circulation. Eur J Clin Invest 2010; 40: 465–476.
16 Seiler C. The collateral circulation of the heart. Springer: London, 2009: 418.
17 Huang G, Wang D, Zeb I, et al. Intra-thoracic fat, cardiometabolic risk factors, and subclinical cardiovascular disease in healthy, recently menopausal women screened for the Kronos Early Estrogen Prevention Study (KEEPS). Atherosclerosis 2012; 221: 198–205.
18 Yerramasu A, Dey D, Venuraju S, et al. Increased volume of epicardial fat is an independent risk factor for accelerated progression of sub-clinical coronary atherosclerosis. Atherosclerosis 2012; 220: 223–230.
19 Sengul C, Cevik C, Ozveren O, et al. Echocardiographic epicardial fat thickness is associated with carotid intima-media thickness in patients with metabolic syndrome. Echocardiography 2011; 288: 853–858.
20 Iacobellis G, Barbaro G. The double role of epicardial adipose tissue as pro- and anti-inflammatory organ. Horm Metab Res 2008; 40: 442–445.
21 Kocaman SA, Yağcı MR, Yağcı M, et al. Endothelial progenitor cells (CD34+/KDR+) and monocytes may provide the development of good coronary collaterals despite the vascular risk factors and extensive atherosclerosis. Anatol Kardiyol Derg 2011; 11: 290–299.
22 Sahinarslan A, Kocaman SA, Topal S, et al. Relation between serum monocyte chemoattractant protein-1 and coronary collateral development. Coron Artery Dis 2010; 21: 455–459.
23 Park HJ, Chang K, Park CS, et al. Coronary collaterals: the role of MCP-1 during the early phase of acute myocardial infarction. Int J Cardiol 2008; 130: 409–413.
24 Rocic P. Why is coronary collateral growth impaired in type II diabetes and the metabolic syndrome? Vasc Pharmacol 2012; 57: 179–186.
25 Hassan M, Latif N, Yacoub M. Adipose tissue: friend or foe? Nat Rev Cardiol 2012; 9: 689–702.
26 Iacobellis G, Malavazos AE, Corsi MM. Epicardial fat: from the biomolecular aspects to the clinical practice. Int J Biochem Cell Biol 2011; 43: 1651–1654.
27 Sacks HS, Fain JN. Human epicardial fat: what is new and what is missing? Clin Exp Pharmacol Physiol 2011; 38: 879–887.
28 Imoto-Tsubakimoto H, Takahashi T, Ueyama T, et al. Seryglycin is a novel adipocytokine highly expressed in epicardial adipose tissue. Biochem Biophys Res Commun 2013; 432: 105–110.
29 Aydin H, Toprak A, Deyneli O, et al. Epicardial fat tissue thickness correlates with endothelial dysfunction and other cardiovascular risk factors in patients with metabolic syndrome. Metab Syndr Relat Disord 2010; 8: 229–234.